Module 6: Genetic Toxicology
Recorded On: 08/05/2021
This module will provide an overview of genetic toxicology with a focus on the ICH S2(R1) guideline. Genetic toxicology testing is conducted to assess the ability of drugs to induce gene mutations as well as chromosomal damage (i.e., clastogenicity and aneugenicity). A battery of tests is used to evaluate these endpoints with the goal of predicting human carcinogenic potential. The presentation will cover both in vitro and in vivo genetic toxicology tests with specific discussion of principles and mechanisms, study design, and data interpretation. Decision-making, including discussion of follow-up strategies to mitigate concern with positive results, will be reviewed. In addition, differences in genetic toxicology testing strategies for small-molecule drugs, non-small-molecule drugs, and impurities will be described. Finally, key points will be highlighted through the use of case studies.
Mark Powley, PhD
Distinguished Research Scientist
Merck & Co., Inc.
Dr. Mark Powley received a PhD in toxicology from Purdue University and completed postdoctoral training at the University of North Carolina – Chapel Hill. From 2004 to 2009 he worked in the general toxicology, biochemical toxicology, and genetic toxicology groups at Merck & Co. In 2009 he moved to the US FDA Center for Drug Evaluation and Research (CDER), Office of New Drugs. In addition to reviewing nonclinical data, Dr. Powley co-chaired CDER pharmacology/toxicology subcommittees focused on genetic toxicology as well as computational toxicology. He was a member of the Genetic Toxicology Association Board of Directors from 2009–2012, serving as chair in 2011–2012. Dr. Powley rejoined Merck & Co. in 2017 and is currently a Distinguished Research Scientist within the Nonclinical Drug Safety organization. His primary role involves supporting mutagenic and non-mutagenic impurity safety assessment efforts.